己二烯雌酚 | 13029-44-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 己二烯雌酚
• 中文别名: 已二烯雌酚
• 英文名称: dienestrol
• 英文别名: dienoestrol；(4,4'-((2E,4E)-hexa-2,4-diene-3,4-diyl)diphenol)；trans-3,4-bis(4-hydroxyphenyl)-2,4-hexadiene；E,E-dienestrol；4-[(2E,4E)-4-(4-hydroxyphenyl)hexa-2,4-dien-3-yl]phenol
• CAS: 13029-44-2
• 化学式: C₁₈H₁₈O₂
• 分子量: 266.34
• InChiKey: NFDFQCUYFHCNBW-SCGPFSFSSA-N

物化性质

• 熔点：
  224-226°C
• 沸点：
  349.54°C (rough estimate)
• 密度：
  1.1305 (rough estimate)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）
• 颜色/状态：
  MINUTE NEEDLES FROM DILUTE ALC
• 气味：
  Odorless
• 水溶性：
  -4.95
• 稳定性/保质期：
  Sensitive to light
• 碰撞截面：
  153.2 Ų [M+Na]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

ADMET

代谢

肝脏的。

Hepatic.

来源:DrugBank

代谢

雌二醇生成兔子的雌二醇-β-D-葡萄糖苷酸酯。

DIENESTROL YIELDS DIENESTROL-BETA-D-GLUCURONIDE IN RABBITS.

来源:Hazardous Substances Data Bank (HSDB)

代谢

地亚烯雌酚是灵长类动物和小鼠中已知的己烯雌酚的代谢物；它会转化为omega-羟基-地亚烯雌酚，以结合形式排出体外...给兔子口服地亚烯雌酚剂量后，它们在尿液中排出了地亚烯雌酚葡萄糖苷酸酯...。

DIENESTROL IS A KNOWN METABOLITE OF DIETHYLSTILBESTROL IN PRIMATES & MICE; IT IS CONVERTED TO OMEGA-HYDROXY-DIENESTROL, WHICH IS EXCRETED IN CONJUGATED FORM ... RABBITS GIVEN ORAL DOSES OF DIENESTROL EXCRETED DIENESTROL GLUCURONIDE IN THEIR URINE ... .

来源:Hazardous Substances Data Bank (HSDB)

代谢

给予口服二烯雌酚的兔子在其尿液中排泄出了二烯雌酚葡萄糖苷酸。

RABBITS GIVEN ORAL DOSES OF DIENESTROL EXCRETED DIENESTROL GLUCURONIDE IN THEIR URINE ... .

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

与雌激素同时使用可能会改变糖皮质激素的代谢和蛋白结合，导致清除率降低、消除半衰期延长以及糖皮质激素的治疗效果和毒性作用增加。

Concurrent use with estrogens may alter the metabolism and protein binding of glucocorticoids, leading to decreased clearance, increased elimination half-life, and increased therapeutic and toxic effects of the glucocorticoids.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

雌激素可能会导致闭经，干扰溴隐亭的效果。/雌激素/

Estrogens may cause amenorrhea, interfering with effects of bromocriptine. /Estrogen/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

钙补充剂：与雌激素同时使用可能增加钙的吸收。/雌激素/

Calcium supplements: concurrent use with estrogens may increase calcium absorption. /Estrogen/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

与雌激素同时使用可能会增强由垂体促肾上腺皮质激素诱导的内源性皮质醇的抗炎作用。/雌激素/

Concurrent use with estrogens may potentiate the anti-inflammatory effects of endogenous cortisol induced by corticotropin. /Estrogen/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 医疗监测

以下内容可能在患者监测中尤为重要（根据病情，某些患者可能需要进行其他检查）：... 肝功能测定（推荐定期进行，特别是在患有或疑似患有肝病的患者治疗期间）；血脂谱测定，血清（推荐每年进行一次，尤其是在服用孕激素的接受雌激素替代疗法的女性中）；乳房X光检查（每12个月一次，或按医生确定）；帕帕尼科劳（Pap）涂片检查和体格检查（每6到12个月一次，或按医生确定更频繁地进行，特别关注腹部、乳房和盆腔器官）

The following may be especially important in patient monitoring (other tests may be warranted in some patients, depending on condition): ... Hepatic function determinations (recommended at regular intervals, especially during therapy in patients who have or are suspected of having hepatic disease); Lipid profile determinations, serum (recommended annually in women who are receiving estrogen replacement therapy, especially if taking a progestin); Mammogram (every 12 mo, or as determined by physician) Papanicolaou (Pap) test and Physical examinations (every 6 to 12 mo or more frequently when so determined by physician, with special attention being given to abdomen, breast, and pelvic organs)

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

• 吸收

地诺前列醇的系统吸收和作用方式尚未确定。雌激素扩散进入靶细胞并与其蛋白质受体相互作用。靶细胞包括女性生殖道、乳腺、下丘脑和垂体。雌激素增加肝脏对性激素结合球蛋白（SHBG）、甲状腺结合球蛋白（TBG）和其他血清蛋白的合成，并抑制来自前垂体的促卵泡激素（FSH）。雌激素与黄体酮的联合使用抑制了下丘脑-垂体系统，减少了促性腺激素释放激素（GnRH）的分泌。

Systemic absorption and mode of action of dienestrol are undetermined.Estrogens diffuse into their target cells and interact with a protein receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH).

来源:DrugBank

吸收、分配和排泄

治疗中使用的雌激素很容易通过皮肤、粘膜和胃肠道吸收。当它们用于局部作用时，吸收往往足以引起全身性效果。/雌激素/

ESTROGENS USED IN THERAPY ARE ... READILY ABSORBED THROUGH SKIN, MUCOUS MEMBRANES, AND GI TRACT. WHEN THEY ARE APPLIED FOR LOCAL ACTION, ABSORPTION IS OFTEN SUFFICIENT TO CAUSE SYSTEMIC EFFECTS. /ESTROGENS/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

实际上，工厂工人在没有戴手套的情况下处理己烯雌酚后，出现了男性乳腺发育症。/己烯雌酚/

IN FACTORY WORKERS GYNECOMASTIA HAS FOLLOWED HANDLING OF DIETHYLSTIBESTROL WITHOUT GLOVES. /DIETHYLSTILBESTEROL/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

雌激素的尿排泄率无论是口服还是静脉给药都相当相似，这表明大多数雌激素从胃肠道的吸收是迅速且相当完全的。/雌激素/

URINARY EXCRETION RATE OF ESTROGENS IS QUITE SIMILAR WHETHER AGENTS ARE GIVEN ORALLY OR INTRAVENOUSLY, WHICH SUGGESTS THAT ABSORPTION OF MOST ESTROGENS FROM GI TRACT IS PROMPT & QUITE COMPLETE. /ESTROGENS/

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

雌激素实际上在水中的溶解度极低。当溶解在油中并注射后，它们会被迅速吸收并快速代谢。... 雌激素的灭活主要在肝脏进行。

ESTROGENS ARE PRACTICALLY INSOLUBLE IN WATER. WHEN DISSOLVED IN OIL AND INJECTED, THEY ARE RAPIDLY ABSORBED & QUICKLY METABOLIZED. ... INACTIVATION OF ESTROGEN IS CARRIED OUT MAINLY IN THE LIVER. /ESTROGENS/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R40
• WGK Germany：
  3
• RTECS号：
  SL0580000
• 海关编码：
  2907299090
• 安全说明：
  S22

反应信息

• 作为反应物：
  描述：

  己二烯雌酚 在 钯 、 丙酮 作用下， 生成 己烷雌酚
  参考文献：
  名称：

  Dodds et al., Proceedings of the Royal Society of London. Series B, Biological sciences, 1939, vol. 127, p. 140,153 Anm. 154

  摘要：

  DOI：
• 作为产物：
  描述：

  meso-3,4-bis-(4-hydroxy-phenyl)-hexane-3,4-diol 在 氢氧化钾 、 乙酸酐 、 乙酰氯 作用下， 生成 己二烯雌酚
  参考文献：
  名称：

  Manufacture of dienoestrol

  摘要：

  公开号：

  US02464203A1

文献信息

• [EN] COMPOUNDS AS MODULATORS OF TIGIT SIGNALLING PATHWAY<br/>[FR] COMPOSÉS MODULATEURS DE LA VOIE DE SIGNALISATION DE TIGIT
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2018047139A1

  公开（公告）日：2018-03-15

  The present invention relates to compound of formula (I) as therapeutic agents to modulate the TIGIT signalling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by TIGIT.

  本发明涉及一种化合物，其化学式为（I），作为调节TIGIT信号通路的治疗剂。该发明还涵盖了利用化合物（I）或其立体异构体或其药学上可接受的盐来治疗由TIGIT介导的疾病或紊乱。
• BROMODOMAIN INHIBITORS FOR TREATING DISEASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20160060260A1

  公开（公告）日：2016-03-03

  Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.

  本文披露了一种在治疗溴结构域含蛋白介导的疾病（如癌症）中有用的化合物和组合物，其具有Formula I的结构： 还提供了一种抑制人类或动物主体中溴结构域含蛋白活性的方法。
• [EN] CYCLIC DINUCLEOTIDES AS AGONISTS OF STIMULATOR OF INTERFERON GENE DEPENDENT SIGNALLING<br/>[FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGONISTES DU STIMULATEUR DE LA SIGNALISATION DÉPENDANTE DU GÈNE DE L'INTERFÉRON
  申请人：UNIV TEXAS

  公开号：WO2018156625A1

  公开（公告）日：2018-08-30

  Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.

  本文披露了新的环二核苷酸化合物和组合物，以及它们作为药物治疗疾病的应用。还提供了调节免疫应答以及诱导干扰素基因激活剂（STING）依赖型I干扰素在人类或动物受试者中产生和共调控基因的方法，用于治疗癌症、尤其是转移性实体瘤和淋巴瘤、炎症、过敏和自身免疫疾病、传染病，以及作为抗病毒剂和疫苗佐剂的用途。
• HETEROCYCLIC INHIBITORS OF MCT4
  申请人：Vettore, LLC

  公开号：US20180162822A1

  公开（公告）日：2018-06-14

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一些化合物和组合物，适用于治疗由MCT4介导的疾病，如增殖性和炎症性疾病，其结构如下所示： 还提供了在人类或动物主体中抑制MCT4活性的方法。
• [EN] MCT4 INHIBITORS FOR TREATING DISEASE<br/>[FR] INHIBITEURS DE MCT4 POUR LE TRAITEMENT DE MALADIES
  申请人：VETTORE LLC

  公开号：WO2016201426A1

  公开（公告）日：2016-12-15

  Disclosed herein are compounds and compositions useful in the treatment of MCT4 mediated diseases, such as proliferative and inflammatory diseases, having the structure of Formula I: Methods of inhibition MCT4 activity in a human or animal subject are also provided.

  本文披露了一种在治疗MCT4介导的疾病中有用的化合物和组合物，如增殖性和炎症性疾病，其具有Formula I的结构：还提供了在人类或动物主体中抑制MCT4活性的方法。

表征谱图